OptiBiotix Health (OPTI) AI Stock Analysis

• Market Cap: £5.42M
• Dividend Yield: N/A
• Average Volume (3M): 268.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 103,300,300
• 10 Day Avg. Volume: 266,472
• 30 Day Avg. Volume: 268,800
• PEG Ratio: 0.53
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 20.26
• P/FCF Ratio: -9.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 7.50 p ▲(11.11% Upside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.

Positive Factors

Revenue growth acceleration

Sustained double-digit revenue acceleration indicates improving commercial traction and product adoption by partners. Over 2–6 months this supports scalability: higher revenues can spread fixed R&D and SG&A, improving the path to operating leverage if growth is sustained and order repeatability continues.

Debt-free balance sheet

No debt provides meaningful financial flexibility for a loss-making biotech: it reduces insolvency risk, lowers mandatory cash outflows, and allows management to prioritise commercialization and R&D. This strengthens the company's ability to fund operations or negotiate strategic partnerships without covenant pressure.

Healthy product-level gross margins

A ~38% gross margin in 2024 shows the underlying ingredient business can be economically attractive at the unit level. For a B2B ingredient supplier, durable gross margins support profitable scaling as sales volumes rise and enable reinvestment in formulation, regulatory work and commercial support to drive longer-term margin expansion.

Negative Factors

Persistent negative cash flow

Consistent operating and free cash outflows imply the business is not yet self-funding. Over months this necessitates external funding or equity dilution, constrains marketing and commercial scale-up, and increases execution risk if new financing is delayed or terms are unfavourable.

Deep and worsening net losses

A net margin around -207% shows current revenue does not cover operating costs and undermines return on capital. Persistently large losses erode equity, limit reinvestment capacity, and mean profitability depends on sustained high growth and meaningful cost control, elevating long-term execution risk.

Revenue dependence on partners and external launches

A partner-led B2B model concentrates revenue timing and control with third parties: product launches, marketing, and distribution are outside the company’s direct control. This structure increases variability of orders and makes sustainable growth contingent on partners' execution and renewals over multiple quarters.

OptiBiotix Health Business Overview & Revenue Model

Company Description

OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.

How the Company Makes Money

OptiBiotix primarily makes money by monetising its health-ingredient technologies through B2B commercial agreements rather than selling directly to consumers. Key revenue streams include: (1) Ingredient sales: supplying its proprietary strains/ingredients (and, where applicable, finished ingredient formulations) to brand owners, contract manufacturers and distributors for inclusion in dietary supplements, functional foods and other health products; revenue is recognised from product shipments under supply terms. (2) Licensing and partner-led commercialisation: granting partners rights to use specific OptiBiotix technologies/brands in defined products and/or territories in return for licensing fees and/or ongoing royalties tied to partner sales, where such terms exist in the relevant agreements; the partner typically handles manufacturing, marketing and distribution. (3) Milestone and development payments: receiving non-recurring payments linked to formulation work, regulatory steps, or commercial launch milestones when included in partner contracts. (4) Distribution/territory agreements: earning revenue via arrangements where third-party distributors commercialise OptiBiotix ingredients in particular geographies; income is generated through transfer pricing/wholesale margins on ingredient supply and/or revenue-share mechanisms depending on contract structure. Significant factors influencing earnings include the number and scale of commercial partnerships signed, successful product launches by partners, repeat orders driven by consumer uptake, and the ability to expand into new territories or application categories. Specific partner names, royalty rates, or the exact split of revenue by stream are null.

OptiBiotix Health Financial Statement Overview

Summary

Revenue growth accelerated in 2024 (+52.9% YoY), but profitability remains very weak with large net losses relative to revenue and continued negative cash flow/free cash flow. The balance sheet is a key offset (no debt, sizable equity), but ongoing losses and cash burn keep the overall financial profile below average.

Income Statement

Revenue growth accelerated in 2024 (+52.9% YoY), showing improving commercial traction. However, profitability remains weak: despite positive gross margin (~38% in 2024), the company is still deeply loss-making with very large operating and net losses relative to revenue (2024 net margin about -207%), and margins deteriorated versus the unusually strong profit levels reported in 2020–2022. Overall, growth is encouraging, but the earnings profile is not yet sustainable.

Balance Sheet

The balance sheet is a clear strength, with zero total debt in 2023–2024 and a net-cash-like posture implied by no leverage. Equity remains sizable (2024 stockholders’ equity ~8.4m vs. assets ~9.0m), providing financial flexibility. The main weakness is persistently negative returns in the last two years (2023–2024), indicating the capital base is not currently generating profits.

Cash Flow

Cash generation is a major pressure point: operating cash flow and free cash flow are consistently negative across the period, including 2024 (both about -1.77m). Cash burn worsened in absolute terms from 2023 to 2024, and cash flow does not yet reflect a self-funding model. While free cash flow moved modestly year-to-year in places, the overall pattern is continued outflows that likely require ongoing funding support.

Breakdown	Jun 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	870.00K	644.00K	457.00K	2.21M	1.52M
Gross Profit	331.00K	320.00K	244.00K	1.12M	879.82K
EBITDA	-2.06M	-1.84M	2.75M	6.51M	6.31M
Net Income	-1.80M	-2.04M	2.59M	6.26M	5.80M
Balance Sheet
Total Assets	9.04M	9.40M	11.55M	20.14M	13.70M
Cash, Cash Equivalents and Short-Term Investments	739.00K	635.00K	1.05M	2.01M	864.68K
Total Debt	0.00	0.00	0.00	819.36K	771.76K
Total Liabilities	647.00K	532.00K	643.00K	1.97M	1.85M
Stockholders Equity	8.40M	8.87M	10.90M	18.14M	11.82M
Cash Flow
Free Cash Flow	-1.77M	-1.53M	-1.28M	-1.76M	-1.28M
Operating Cash Flow	-1.77M	-1.53M	-1.11M	-1.56M	-927.96K
Investing Cash Flow	587.00K	1.11M	-331.00K	-193.51K	-350.35K
Financing Cash Flow	1.28M	0.00	485.00K	2.90M	1.69M

OptiBiotix Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.00M	-0.92	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCF	49 Neutral	£4.41M	-0.88	-53.79%	―	―	85.56%
OPTI	43 Neutral	£5.42M	-2.61	-2.42%	―	―	―
CIZ	43 Neutral	£9.91M	-4,173.96	-433.59%	―	―	―
SBTX	43 Neutral	£18.14M	-54.98	-10.01%	―	283.74%	78.57%
NFX	42 Neutral	£4.96M	-5.98	-153.80%	―	―	-616.67%

OptiBiotix Health Corporate Events

OptiBiotix Trials WellBiome to Boost Cardiac Surgery Outcomes and Cut NHS Costs

OptiBiotix Health has launched a double-blind, placebo-controlled clinical trial with Hull University Teaching Hospital NHS Trust to assess whether its patented prebiotic fibre complex WellBiome can improve cardiac surgery outcomes and reduce costs for the NHS. The six-week pre-operative supplementation study of up to 60 patients will measure time in intensive care, overall hospital stay and post-operative complications, alongside a formal cost-savings analysis.

WellBiome, developed with UK universities, is designed to enhance gut microbiome diversity and carries European and US health claims spanning gut, bone, cardiovascular, muscle, brain and psychological health, aligning with rising global consumer focus on gut health. If the trial demonstrates clinical and economic benefits, WellBiome could be positioned as a standard preoperative care option for NHS surgical patients, strengthening OptiBiotix’s role in evidence-based microbiome interventions and potentially opening broader healthcare adoption.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.

OptiBiotix Reassures Investors on Stakes in Affiliates as Cash and Sales Momentum Improve

OptiBiotix Health addressed investor concerns arising from recent announcements by SkinBioTherapeutics, stressing it has no current intention to sell its 5.64% stake in that company or its shares in ProBiotix Health. Management highlighted that the market volatility does not alter its strategic holdings and that it views the fundamentals of its own business as strong.

The group reported an unaudited cash balance of just over £1 million at 31 December 2025, up from £739,000 a year earlier, and said it has no present need to raise new funds. It is concentrating on boosting sales, improving margins and cutting costs across business units, with over £800,000 of 2026 orders already secured and ecommerce operations, including Amazon and China channels, either now profitable or expected to turn profitable soon.

The board pointed to strong momentum from first-generation products and progress on second-generation launches, citing material advances in its SweetBiotix range and a large 24-metric-tonne order from partner Meelung. Executives argued that these developments, combined with tighter financial discipline and clearer profit-and-loss accountability for each regional and channel unit, leave OptiBiotix in its strongest operating position to date despite external market uncertainties.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.

OptiBiotix Secures Record Early 2026 Orders as SlimBiome Demand Surges

OptiBiotix Health has secured four significant orders totalling 24 metric tonnes of its flagship weight management ingredient SlimBiome from Taiwanese distributor Meelung Trading, to be delivered in staged shipments throughout 2026, reflecting rapid sales growth since their agreement in mid-2025. Together with a previously announced low six-figure order from a major weight management company and commitments from two other partners, the group has locked in more than £800,000 of non-cancellable orders early in the year, giving it improved visibility, supply-chain efficiencies and pricing leverage as it targets the rapidly expanding “natural alternative to GLP-1” market, where SlimBiome’s clinical backing and regulatory claims position the company for further growth and a stronger competitive footing going into 2026.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.

OptiBiotix Launches Interactive Investor Hub to Deepen Shareholder Engagement

OptiBiotix Health has launched an interactive investor website that consolidates its corporate, commercial and research content into a single digital hub aimed at improving transparency and engagement with current and prospective shareholders. The platform hosts regulatory announcements, financial reports, presentations, research overviews and partner interviews, while also enabling investors to submit questions directly to management for timely responses, a move the company says will provide richer context on commercial progress and product development—particularly around second-generation offerings like SweetBiotix®—and strengthen its communication strategy as it pursues growth in the microbiome health sector.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.